Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Amortization of Deferred Charges: 2014-2025

Historic Amortization of Deferred Charges for Zevra Therapeutics (ZVRA) over the last 8 years, with Sep 2025 value amounting to $685,000.

  • Zevra Therapeutics' Amortization of Deferred Charges fell 12.07% to $685,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 million, marking a year-over-year increase of 60.89%. This contributed to the annual value of $2.1 million for FY2024, which is N/A change from last year.
  • According to the latest figures from Q3 2025, Zevra Therapeutics' Amortization of Deferred Charges is $685,000, which was down 0.58% from $689,000 recorded in Q2 2025.
  • In the past 5 years, Zevra Therapeutics' Amortization of Deferred Charges ranged from a high of $779,000 in Q3 2024 and a low of $150,000 during Q1 2021.
  • Moreover, its 2-year median value for Amortization of Deferred Charges was $663,000 (2025), whereas its average is $589,429.
  • In the last 5 years, Zevra Therapeutics' Amortization of Deferred Charges tumbled by 87.94% in 2021 and then skyrocketed by 177.41% in 2025.
  • Zevra Therapeutics' Amortization of Deferred Charges (Quarterly) stood at $150,000 in 2021, then reached $600,000 in 2024, then dropped by 12.07% to $685,000 in 2025.
  • Its Amortization of Deferred Charges was $685,000 in Q3 2025, compared to $689,000 in Q2 2025 and $663,000 in Q1 2025.